However, recent data showing dramatic and prolonged responses in BM patients treated with EGFR and ALK TKIs have suggested that delaying LAT and WBRT may be a valid treatment option for patients with asymptomatic BM from NSCLC, especially for those with EGFR-activating mutations or harboring ALK rearrangement. Here, EGFR is linked to non-small cell lung carcinoma.